Linezolid Tablet
Product Images NDC 64980-561

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Linezolid (NDC 64980-561). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Linezolid-graph01 (Linezolid Graph01)

A line graph depicting the plasma concentration of Linezolid (600 mg oral) over 12 hours post-dose. The y-axis shows Linezolid plasma concentration in µg/mL, and the x-axis shows time after dose in hours. Data points illustrate concentration peaking early and gradually decreasing with error bars at each time point.*

FDA Label Image

Linezolid-label01 (Linezolid Label01)

Linezolid Tablets USP 600 mg oral tablets packaging label from Rising Pharma Holdings, Inc. The label indicates 20 tablets in the container, with dosage and storage instructions. The label includes the NDC 64980-561-02 and features a barcode.*

FDA Label Image

Linezolid-struct (Linezolid Struct)

Chemical structure diagram of the active ingredient linezolid, showing its molecular arrangement with included oxygen, nitrogen, fluorine, and carbon groups.*

FDA Label Image

Linezolid-table (Linezolid Table)

A data table comparing cure rates by source of infection for Linezolid 600 mg every 12 hours versus 200 mg every 12 hours. It lists infection sites such as any site, any site with associated bacteremia, bacteremia of unknown origin, skin and skin structure, urinary tract, pneumonia, and other sources including hepatic abscess and catheter-related infection, with cure counts and percentages for each dosage.*

FDA Label Image

Linezolid-table02 (Linezolid Table02)

Adverse reactions data table comparing Linezolid (400 mg orally every 12 hours and 600 mg every 12 hours) with clarithromycin and other comparator drugs. The table lists percentages of various side effects such as headache, diarrhea, nausea, vomiting, dizziness, rash, anemia, taste alteration, fungal infections, and abdominal pain among patients with uncomplicated skin infections and other indications.*

FDA Label Image

Linezolid-table03 (Linezolid Table03)

A table presenting adverse reactions rates for Linezolid compared to Cefadroxil and Vancomycin. It differentiates between uncomplicated skin and skin structure infections and all other indications, showing percentages of patients experiencing specific side effects such as diarrhea, vomiting, headache, and anemia.*

FDA Label Image

Linezolid-table06 (Linezolid Table06)

A laboratory assay data table comparing blood values (hemoglobin, platelet count, WBC, neutrophils) for linezolid versus cefadroxil in uncomplicated skin and skin structure infections, and linezolid versus vancomycin in all other indications. Includes footnotes on dosing for different age groups and definitions for lower limit of normal values.*

FDA Label Image

Linezolid-table07 (Linezolid Table07)

A data table presenting laboratory assay results comparing Linezolid to Cefadroxil and Vancomycin for uncomplicated skin and skin structure infections and all other indications. The table includes values for ALT, Lipase, Amylase, Total bilirubin, and Creatinine with footnotes explaining dosing and patient age groups.*

FDA Label Image

Linezolid-table08 (Linezolid Table08)

Pharmacokinetic data table for Linezolid tablets and suspensions at various doses and administration routes. It lists maximum and minimum plasma concentrations, time to maximum concentration, area under the curve, elimination half-life, and systemic clearance values for 400 mg tablet, 600 mg tablet, 600 mg IV injection, and 600 mg oral suspension single and multiple doses.*

FDA Label Image

Linezolid-table09 (Linezolid Table09)

A data table presenting pharmacokinetic parameters of linezolid across different age groups, including neonatal, infant, pediatric, adolescent, and adult subjects. It shows values for maximum plasma concentration (Cmax), volume of distribution (Vss), area under the concentration-time curve (AUC), apparent elimination half-life (t1/2), and systemic clearance (CL), with corresponding units and percentage variability.*

FDA Label Image

Linezolid-table10 (Linezolid Table10)

A data table comparing pharmacokinetic parameters for Linezolid and its metabolites (Metabolite A and Metabolite B) in subjects with varying degrees of renal function: healthy subjects, moderate renal impairment, and severe renal impairment. It shows values for area under the curve (AUC) and half-life (t1/2) for each group, indicating changes in drug and metabolite levels relative to renal function.*

FDA Label Image

Linezolid-table11 (Linezolid Table11)

A data table presenting pharmacokinetic parameters for Linezolid and its metabolites (Metabolite A and Metabolite B) in ESRD subjects. The table lists AUC0-12 and half-life (t1/2) values after the last dose, with footnotes noting the timing between hemodialysis sessions and that Metabolite B is the major metabolite of Linezolid.*

FDA Label Image

Linezolid-table13 (Linezolid Table13)

A data table comparing cure rates of three pathogens—Staphylococcus aureus, Methicillin-resistant S. aureus, and Streptococcus pneumoniae—when treated with Linezolid or Vancomycin. The table shows the number and percentage cured for each pathogen and antibiotic treatment.*

FDA Label Image

Linezolid-table14 (Linezolid Table14)

A data table comparing cure rates of pathogens treated with Linezolid versus Oxacillin/Dicloxacillin. It lists pathogens including Staphylococcus aureus, Methicillin-resistant S. aureus, Streptococcus agalactiae, and Streptococcus pyogenes, showing the number and percentage cured (n/N %) for each treatment group.*

FDA Label Image

Linezolid-table15 (Linezolid Table15)

A table showing the cure rates of pathogens treated with Linezolid compared to a comparator. It lists pathogens Staphylococcus aureus, Methicillin-resistant S. aureus, and Streptococcus agalactiae with corresponding cure numbers and percentages for Linezolid and a comparator.*

FDA Label Image

Linezolid-table16 (Linezolid Table16)

A data table comparing Linezolid and Vancomycin effectiveness across populations labeled ITT, MITT, and Clinically Evaluable. The table includes results for any diagnosis, complicated skin and skin structure infections, and nosocomial pneumonia, with numerical counts and percentages for each category. MITT is defined as ITT patients with an isolated Gram-positive pathogen at baseline.*

FDA Label Image

Linezolid-table17 (Linezolid Table17)

A data table comparing microbiological evaluation results for Linezolid and Vancomycin against various pathogens, including Vancomycin-resistant Enterococcus faecium, Staphylococcus aureus, Methicillin-resistant S. aureus, and Streptococcus pyogenes, with percentages and sample sizes shown for each treatment and pathogen.*

FDA Label Image

Linezolidtable04 (Linezolidtable04)

A data table comparing laboratory assay results for hematologic parameters (Hemoglobin, Platelet count, WBC, Neutrophils) across different treatments: Linezolid 400 mg every 12 hours and Clarithromycin 250 mg every 12 hours for uncomplicated skin and skin structure infections, and Linezolid 600 mg every 12 hours versus other comparators for all other indications. Footnotes define comparator drugs and thresholds for laboratory values.*

FDA Label Image

Linezolidtable05 (Linezolidtable05)

Table presenting laboratory assay values for Linezolid in different dosing regimens compared with clarithromycin and other comparators. Measurements include AST, ALT, LDH, alkaline phosphatase, lipase, amylase, total bilirubin, BUN, and creatinine, with values shown for uncomplicated skin infections and all other indications.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.